Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nanobiotix stock price, quote, forecast and news

NANO.PA
FR0011341205
A1J7EB

Price

4.51
Today +/-
-0.14
Today %
-2.97 %
P

Nanobiotix stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nanobiotix stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nanobiotix stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nanobiotix stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nanobiotix's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nanobiotix Stock Price History

DateNanobiotix Price
9/20/20244.51 undefined
9/19/20244.65 undefined
9/18/20244.45 undefined
9/17/20244.47 undefined
9/16/20244.38 undefined
9/13/20244.36 undefined
9/12/20244.50 undefined
9/11/20244.55 undefined
9/10/20244.58 undefined
9/9/20244.46 undefined
9/6/20244.45 undefined
9/5/20244.60 undefined
9/4/20244.62 undefined
9/3/20244.70 undefined
9/2/20244.88 undefined
8/30/20244.98 undefined
8/29/20244.88 undefined
8/28/20245.21 undefined
8/27/20244.64 undefined
8/26/20244.66 undefined
8/23/20244.71 undefined

Nanobiotix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nanobiotix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nanobiotix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nanobiotix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nanobiotix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nanobiotix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nanobiotix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nanobiotix’s growth potential.

Nanobiotix Revenue, EBIT and net profit per share

DateNanobiotix RevenueNanobiotix EBITNanobiotix Net Income
2029e159.4 M undefined0 undefined70.49 M undefined
2028e58.61 M undefined-12.25 M undefined-26.25 M undefined
2027e30.12 M undefined-38.38 M undefined-43.27 M undefined
2026e46.36 M undefined-18.54 M undefined-26.75 M undefined
2025e17.79 M undefined-48.96 M undefined-49.17 M undefined
2024e28.85 M undefined-38.14 M undefined-41.97 M undefined
202330.06 M undefined-26.78 M undefined-39.7 M undefined
20220 undefined-46.7 M undefined-57.04 M undefined
202110,000 undefined-52.58 M undefined-47 M undefined
202050,000 undefined-36.43 M undefined-33.59 M undefined
201968,000 undefined-46.78 M undefined-50.92 M undefined
2018116,000 undefined-30.07 M undefined-30.35 M undefined
2017252,000 undefined-25.27 M undefined-26.14 M undefined
20161.56 M undefined-21.85 M undefined-21.88 M undefined
2015265,540 undefined-17.14 M undefined-17 M undefined
2014967,500 undefined-9.62 M undefined-9.56 M undefined
2013180,000 undefined-8.18 M undefined-8.14 M undefined
201270,000 undefined-5.15 M undefined-5.33 M undefined
20111.36 M undefined-5.23 M undefined-5.25 M undefined
20101.13 M undefined-4.1 M undefined-4.09 M undefined
20092.77 M undefined-1.5 M undefined-1.51 M undefined

Nanobiotix Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
21100001000000302817463058159
--50.00--------------6.67-39.29170.59-34.7893.33174.14
100.00100.00100.00------------------
211000000002240000000
-1-4-5-5-8-9-17-21-25-30-46-36-52-46-26-38-48-18-38-120
-50.00-400.00-500.00-----2,100.00-------86.67-135.71-282.35-39.13-126.67-20.69-
-1-4-5-5-8-9-17-21-26-30-50-33-47-57-39-41-49-26-43-2670
-300.0025.00-60.0012.5088.8923.5323.8115.3866.67-34.0042.4221.28-31.585.1319.51-46.9465.38-39.53-369.23
0.981.51.688.9911.7612.8714.1415.2817.4819.6321.6324.3934.7334.8536.93000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Nanobiotix Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nanobiotix is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200920102011201220132014201520162017201820192020202120222023
                             
2.15.680.912.36532.991721.0647.2136.235.09119.1583.9241.3975.28
0000000.080.010.170.030.010.0600.12.97
0001.071.692.044.6604.735.338.353.826.937.896.53
00000000000001000
0.180.090.090.110.20.471.215.7611.12.672.222.212.982.56
2.285.770.9913.546.8935.522.9526.8253.1142.6546.13125.2593.0652.4687.34
0.540.640.510.420.471.292.432.432.992.889.398.268.197.126.25
0.020.040.060.070.070.251.031.081.230.560.530.510.520.290.3
0000000000003.935.290
1001001010107213610216321418
000000000000000
0000000000000-00
0.570.680.580.490.551.553.473.584.363.5410.088.7812.6412.76.56
2.856.451.5714.037.4437.0526.4230.457.4746.256.21134.03105.765.1693.9
                             
0.110.230.230.320.320.420.420.480.590.590.671.031.051.051.41
515.5915.615.5115.5551.8452.6374.3123.78122.8153.14255.74255.77255.76312.74
-3.18-9.93-14.91-4.95-12.47-21.87-37.36-57.4-80.94-109.4-155.98-186.66-230.46-284.32-316.51
000000079514381434555642700739
000000000000000
1.935.890.9210.883.430.3915.6917.4643.9514.37-1.7470.6626.99-26.82-1.61
0.450.610.40.281.352.233.594.375.14000000
0.350.510.60.610.961.31.58004.115.136.535.086.67.38
0.390.420.421.270.970.890.863.033.997.498.638.1424.3627.2838.06
000000000000000
0.02000001.071.080.4300.594.377.44.064.43
1.211.541.422.163.284.427.18.499.5611.5914.3519.0436.8537.9449.87
0001.070.8823.534.343.7516.7340.5641.1335.5646.3543.67
000000000000000
0.520.510.570.10.10.310.170.180.233.633.213.392.582.532.2
0.520.510.571.170.982.313.74.523.9820.3643.7744.5238.1348.8845.87
1.732.051.993.334.266.7310.81313.5531.9558.1163.5674.9886.8195.74
3.667.942.9114.217.6637.1226.4930.4657.4946.3256.37134.23101.976094.13
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nanobiotix provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nanobiotix's financial health and stability.

Assets

Nanobiotix's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nanobiotix must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nanobiotix after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nanobiotix's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20092010201120122013201420152016201720182019202020212022
-1-4-5-5-8-9-17-21-26-30-50-33-47-57
00000000001,0001,0001,0001,000
00000000000000
000000-1111-15112
00000011229-1416
0000000000001,0000
00000000000000
-1-4-4-3-6-8-16-18-20-25-41-27-29-37
00000000-10-1000
-1-4400-1-20-10-1000
-1-4400-1-20000000
00000000000000
0-20001210151290-1
2100160360235302911300
38015037322481441111-5-5
----2.00----1.00-3.00---11.00-4.00-4.00
00000000000000
00011-728-15426-11-184-35-42
-1.65-4.18-4.87-3.79-6.83-8.56-16.82-18.28-22.39-26.49-42.61-27.65-30.11-37.2
00000000000000

Nanobiotix stock margins

The Nanobiotix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nanobiotix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nanobiotix.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nanobiotix's sales revenue. A higher gross margin percentage indicates that the Nanobiotix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nanobiotix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nanobiotix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nanobiotix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nanobiotix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nanobiotix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nanobiotix Margin History

Nanobiotix Gross marginNanobiotix Profit marginNanobiotix EBIT marginNanobiotix Profit margin
2029e26,500 %0 %44.22 %
2028e26,500 %-20.91 %-44.79 %
2027e26,500 %-127.43 %-143.67 %
2026e26,500 %-39.99 %-57.71 %
2025e26,500 %-275.24 %-276.43 %
2024e26,500 %-132.19 %-145.47 %
202326,500 %-89.09 %-132.08 %
202226,500 %0 %0 %
202126,500 %-525,790 %-470,030 %
20204,640 %-72,856 %-67,180 %
201926,500 %-68,792.65 %-74,875 %
201826,500 %-25,919.83 %-26,159.48 %
201726,500 %-10,026.59 %-10,374.21 %
201626,500 %-1,402.65 %-1,404.31 %
201526,500 %-6,455.39 %-6,403.21 %
201426,500 %-994.29 %-987.76 %
201326,500 %-4,544.44 %-4,522.22 %
201226,500 %-7,357.14 %-7,614.29 %
2011100 %-384.56 %-386.03 %
2010100 %-362.83 %-361.95 %
200996.39 %-54.15 %-54.51 %

Nanobiotix Stock Sales Revenue, EBIT, Earnings per Share

The Nanobiotix earnings per share therefore indicates how much revenue Nanobiotix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nanobiotix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nanobiotix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nanobiotix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nanobiotix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nanobiotix Revenue, EBIT and net profit per share

DateNanobiotix Sales per ShareNanobiotix EBIT per shareNanobiotix Earnings per Share
2029e3.38 undefined0 undefined1.5 undefined
2028e1.24 undefined0 undefined-0.56 undefined
2027e0.64 undefined0 undefined-0.92 undefined
2026e0.98 undefined0 undefined-0.57 undefined
2025e0.38 undefined0 undefined-1.04 undefined
2024e0.61 undefined0 undefined-0.89 undefined
20230.81 undefined-0.73 undefined-1.08 undefined
20220 undefined-1.34 undefined-1.64 undefined
20210 undefined-1.51 undefined-1.35 undefined
20200 undefined-1.49 undefined-1.38 undefined
20190 undefined-2.16 undefined-2.35 undefined
20180.01 undefined-1.53 undefined-1.55 undefined
20170.01 undefined-1.45 undefined-1.5 undefined
20160.1 undefined-1.43 undefined-1.43 undefined
20150.02 undefined-1.21 undefined-1.2 undefined
20140.08 undefined-0.75 undefined-0.74 undefined
20130.02 undefined-0.7 undefined-0.69 undefined
20120.01 undefined-0.57 undefined-0.59 undefined
20110.81 undefined-3.11 undefined-3.13 undefined
20100.75 undefined-2.73 undefined-2.73 undefined
20092.83 undefined-1.53 undefined-1.54 undefined

Nanobiotix business model

Nanobiotix SA is a biotechnology company specializing in the development of nanoparticles used in cancer therapy to increase the effectiveness of radiation therapy. It was founded in 2003 in Paris, France by Dr. Laurent Lévy and his team. The company went public in 2012 and is currently listed on the Euronext Paris exchange. Nanobiotix's business model is based on the production and marketing of nanoparticles called NBTXR3, which enhance the effectiveness of radiation therapy. The company works with various partners to further develop its technology and explore new applications. Nanobiotix has two main divisions: one focused on developing nanoparticles to enhance radiation therapy for cancer, and another dedicated to using nanoparticles as drug carriers. Its flagship product, NBTXR3, is designed specifically for cancer therapy and has shown promising results. Nanobiotix is also working on combining NBTXR3 with immunotherapies to further improve cancer treatment. In summary, Nanobiotix is an innovative company specializing in the development of nanoparticles to enhance radiation therapy for cancer and improve patient treatment. Nanobiotix is one of the most popular companies on Eulerpool.com.

Nanobiotix SWOT Analysis

Strengths

Nanobiotix SA possesses cutting-edge technology, enabling the development of novel therapeutics and diagnostics that have the potential to revolutionize the healthcare industry.

The company holds a robust portfolio of patents, trademarks, and intellectual property rights, providing a competitive advantage and safeguarding their innovative products from competitors' imitation.

Weaknesses

Nanobiotix SA currently has a limited presence in the global market, which restricts its reach and potential customer base.

The company invests a significant amount of resources in research and development efforts, which can pose financial challenges, especially if expected outcomes are not achieved.

Opportunities

The increasing need for advanced and effective therapeutics creates a favorable market environment for Nanobiotix SA to expand its product offerings and capture a larger market share.

The company can explore partnerships with pharmaceutical companies or research institutions to leverage their expertise, gain access to additional resources, and accelerate the development and commercialization of its products.

Threats

The healthcare industry is highly competitive, with numerous companies vying for market share. This poses a threat to Nanobiotix SA's ability to differentiate its products and maintain a competitive edge.

Compliance with stringent regulations and obtaining necessary approvals can be time-consuming and expensive, potentially delaying the company's product launches and hindering its growth.

Nanobiotix Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nanobiotix historical P/E ratio, EBIT, and P/S ratio.

Nanobiotix shares outstanding

The number of shares was Nanobiotix in 2023 — This indicates how many shares 36.928 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nanobiotix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nanobiotix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nanobiotix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nanobiotix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nanobiotix.

Nanobiotix latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20230.1 -0.28  (-374.51 %)2023 Q4
6/30/2023-0.73 -0.8  (-8.93 %)2023 Q2
6/30/2022-0.71 -0.76  (-6.44 %)2022 Q2
12/31/2021-0.71 -0.47  (34.17 %)2021 Q4
6/30/2021-0.66 -0.88  (-32.73 %)2021 Q2
12/31/2020-0.78 -0.49  (36.79 %)2020 Q4
6/30/2020-1.12 -0.91  (18.89 %)2020 Q2
12/31/2019-0.98 -1.2  (-22.98 %)2019 Q4
6/30/2019-0.98 -1.15  (-17.44 %)2019 Q2
12/31/2018-0.67 -0.91  (-35.18 %)2018 Q4
1
2

Nanobiotix list of shareholders

%
Name
Stocks
Change
Date
9.12418 % Qatar Investment Authority4,298,507468,32712/31/2023
6.51445 % Invus Public Equities Advisors, LLC3,069,034012/31/2022
2.03574 % Levy (Laurent)959,060012/31/2022
11.93733 % Johnson & Johnson5,623,8165,623,81611/23/2023
0.46544 % Generali Investments Partners S.p.A. SGR219,27302/29/2024
0.20629 % Nanobiotix SA Employees and Management97,184-261,63412/31/2022
0.17799 % State Street Global Advisors (US)83,8531,8012/29/2024
0.16919 % Talence Gestion, SAS79,70914,17311/30/2023
0.11887 % Claresco Finance S.A.56,0004,0002/29/2024
0.10613 % Hermant (Anne-Juliette)50,00050,00012/31/2022
1
2
3

Nanobiotix Executives and Management Board

Dr. Laurent Levy51
Nanobiotix Chairman of the Management Board, Chief Executive Officer, Co-Founder
Compensation 553,065
Mr. Bart Van Rhijn50
Nanobiotix Chief Financial Officer, Member of the Management Board
Compensation 443,857
Ms. Anne-Juliette Hermant49
Nanobiotix Chief People Officer, Member of the Management Board
Compensation 287,543
Mr. Enno Spillner53
Nanobiotix Independent Member of the Supervisory Board
Compensation 50,000
Ms. Anne-Marie Graffin62
Nanobiotix Independent Vice Chairwoman of the Supervisory Board (since 2014)
Compensation 42,000
1
2

Most common questions regarding Nanobiotix

What values and corporate philosophy does Nanobiotix represent?

Nanobiotix SA is a leading company that represents several core values and a strong corporate philosophy. With a focus on innovation and cutting-edge technology, Nanobiotix is dedicated to revolutionizing cancer treatment with its proprietary nanomedicine platform. The company believes in the power of collaboration, working closely with research institutions, healthcare professionals, and patients to develop groundbreaking therapies. Nanobiotix is committed to excellence, ensuring the highest quality in its products and services. Moreover, the company is guided by a sense of responsibility towards patients and society, striving to make a positive impact in the field of oncology. Nanobiotix SA embodies a vision of advancing cancer care through innovative, patient-centric solutions.

In which countries and regions is Nanobiotix primarily present?

Nanobiotix SA is primarily present in various countries and regions globally. The company has established its presence in Europe, including France, Germany, Spain, and the United Kingdom. Additionally, Nanobiotix SA has expanded its operations and collaborations in the United States, where it aims to advance its innovative solutions. With a rapidly growing international reach, Nanobiotix SA is continuously striving to strengthen its presence in key markets and establish valuable partnerships to further enhance its position in the field of biotechnology and nanomedicine.

What significant milestones has the company Nanobiotix achieved?

Nanobiotix SA, a leading biotechnology company, has achieved several significant milestones. The company's innovative approach to cancer treatment has garnered attention and accolades. Nanobiotix SA successfully completed the Phase III study of its flagship product, NBTXR3, demonstrating its efficacy in improving outcomes for patients with locally advanced soft tissue sarcoma. Additionally, Nanobiotix SA has secured various collaborations and partnerships with renowned organizations, highlighting their commitment to advancing research and development. By consistently pushing boundaries and pioneering new therapeutic solutions, Nanobiotix SA continues to make impressive strides in the field of oncology and remains a prominent player in the industry.

What is the history and background of the company Nanobiotix?

Nanobiotix SA is a French nanomedicine company specializing in the development of innovative cancer therapies. Established in 2003, the company has made significant advancements in the field of nanomedicine, particularly in the area of radiotherapy. Nanobiotix SA's flagship product, NBTXR3, is a first-in-class nanoparticle designed to enhance the efficacy of radiotherapy in various solid tumors. With a strong focus on research and development, Nanobiotix SA has received regulatory approvals in multiple countries and has established strategic collaborations with renowned organizations. As a pioneering player in nanomedicine, Nanobiotix SA is committed to revolutionizing cancer treatment and improving the lives of patients worldwide.

Who are the main competitors of Nanobiotix in the market?

The main competitors of Nanobiotix SA in the market include companies such as CytRx Corporation, DelSiTech Ltd., OncoSec Medical Incorporated, and Sol-Gel Technologies Ltd. These companies operate in the field of oncology and drug delivery technologies, just like Nanobiotix SA. However, Nanobiotix SA differentiates itself through its innovative technology called the NanoXray platform, which enables localized tumor treatment. With its unique approach and strong pipeline, Nanobiotix SA aims to establish a leading position in the global oncology market.

In which industries is Nanobiotix primarily active?

Nanobiotix SA primarily operates in the healthcare and biotechnology industries.

What is the business model of Nanobiotix?

The business model of Nanobiotix SA is focused on developing and commercializing innovative nanoparticle-based therapeutic products for cancer treatment. The company utilizes its proprietary nanotechnology platform, NanoXray, to enhance the efficacy of radiotherapy by targeting tumors. Nanobiotix SA aims to revolutionize cancer treatment by providing personalized and effective therapies through the development of its lead product, NBTXR3. This product has the potential to be used across various cancer indications and has shown promising results in clinical trials. Nanobiotix SA also collaborates with leading academic institutions and pharmaceutical companies to further advance its research and development efforts.

What is the P/E ratio of Nanobiotix 2024?

The Nanobiotix P/E ratio is -3.97.

What is the P/S ratio of Nanobiotix 2024?

The Nanobiotix P/S ratio is 5.77.

What is the AlleAktien quality score of Nanobiotix?

The AlleAktien quality score for Nanobiotix is 6/10.

What is the revenue of Nanobiotix 2024?

The expected Nanobiotix revenue is 28.85 M EUR.

How high is the profit of Nanobiotix 2024?

The expected Nanobiotix profit is -41.97 M EUR.

What is the business model of Nanobiotix

Nanobiotix SA is a French company specializing in the development of nanomedicine for cancer treatment. It has its headquarters in Paris and also has offices in the United States and Asia. The company's flagship product is NBTXR3, a nanoparticle technology platform that enables targeted delivery of radiation and other drugs to tumors, increasing treatment effectiveness. Nanobiotix also conducts research programs to discover and develop new nanoparticle candidates for cancer treatment and collaborates with other pharmaceutical companies through partnerships. Overall, Nanobiotix aims to establish NBTXR3 for use in multiple indications and continues to explore and develop new technologies for fighting cancer.

What is the Nanobiotix dividend?

Nanobiotix pays a dividend of 0 EUR distributed over payouts per year.

How often does Nanobiotix pay dividends?

The dividend cannot currently be calculated for Nanobiotix or the company does not pay out a dividend.

What is the Nanobiotix ISIN?

The ISIN of Nanobiotix is FR0011341205.

What is the Nanobiotix WKN?

The WKN of Nanobiotix is A1J7EB.

What is the Nanobiotix ticker?

The ticker of Nanobiotix is NANO.PA.

How much dividend does Nanobiotix pay?

Over the past 12 months, Nanobiotix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nanobiotix is expected to pay a dividend of 0 EUR.

What is the dividend yield of Nanobiotix?

The current dividend yield of Nanobiotix is .

When does Nanobiotix pay dividends?

Nanobiotix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nanobiotix?

Nanobiotix paid dividends every year for the past 0 years.

What is the dividend of Nanobiotix?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nanobiotix located?

Nanobiotix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nanobiotix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nanobiotix from 9/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Nanobiotix pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Nanobiotix in the year 2023?

In the year 2023, Nanobiotix distributed 0 EUR as dividends.

In which currency does Nanobiotix pay out the dividend?

The dividends of Nanobiotix are distributed in EUR.

All fundamentals about Nanobiotix

Our stock analysis for Nanobiotix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanobiotix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.